Valneva SE, a new company created by the merger of two biotech companies, the Austrian Intercell AG and the French Vivalis SA, starts trading today on the Vienna Stock Exchange. The ordinary shares of Valneva SE will trade on the Second Regulated Market of the Vienna SE and also on Compartment B, a regulated market of NYSE Euronext Paris. The preferred shares will also be included in trading on the Third Market of the Vienna Stock Exchange and of NYSE Euronext. Erste Group Bank AG will act as specialist for the stocks and provide liquidity in continuous trading on the prime market.
“The listing on the Vienna Stock Exchange generates optimal coverage by domestic analysts and will help draw investor attention as well as public attention to the company. The listing in Vienna also ensures that our company continues to have excellent access to international investors,” explained Reinhard Kandera, CFO of Valneva SE.
“Valneva SE is one more significant international player to join the prime market. We welcome its listing, as it will most certainly enhance the price list of the Vienna Stock Exchange,” said Birgit Kuras, member of the Management Board of the Vienna Stock Exchange.
The newly founded company Valneva SE, headquartered in Lyon, is a biotech company specializing in vaccinations and antibodies.
